Related Experiment Video

Updated: Nov 4, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION

Hiroshi Sakai1, Masahiro Morise2, Terufumi Kato3

  • 1Department of Thoracic Oncology, Saitama Cancer Center, Ina, Japan.

Japanese Journal of Clinical Oncology
|May 26, 2021
PubMed
Abstract

Insights

Tepotinib showed significant efficacy in Japanese patients with advanced non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping. The treatment was well-tolerated and manageable for patients with this specific NSCLC subtype.

Area of Science:

  • Oncology
  • Medical Genetics
  • Pharmacology

Background:

  • MET exon 14 skipping mutations are key oncogenic drivers in 3-4% of non-small cell lung cancer (NSCLC).
  • The MET inhibitor tepotinib has shown promise in treating NSCLC patients with MET exon 14 skipping.
  • This study focuses on Japanese patients within the Phase II VISION trial, assessing tepotinib's efficacy and safety.

Purpose of the Study:

  • To evaluate the efficacy and safety of tepotinib in Japanese patients with advanced/metastatic NSCLC harboring MET exon 14 skipping mutations.
  • To analyze objective response rate (ORR), duration of response, and progression-free survival (PFS).
  • To assess the impact of tepotinib on patients' quality of life.

Main Methods:

  • An open-label, single-arm, Phase II clinical trial (VISION study).
  • Japanese patients with advanced/metastatic NSCLC and MET exon 14 skipping received oral tepotinib 500 mg daily.
  • Primary endpoint: objective response by independent review; subgroup analyses for Japanese patients were preplanned.

Main Results:

  • Objective response rate (ORR) was 60.0% in 15 evaluable Japanese patients.
  • ORR was higher in patients identified by liquid biopsy (87.5%) compared to tissue biopsy (50.0%).
  • Median duration of response and PFS were not reached; quality of life was maintained. Common adverse events included blood creatinine increase and peripheral edema.

Conclusions:

  • Tepotinib demonstrates robust and durable efficacy in Japanese patients with advanced NSCLC harboring MET exon 14 skipping.
  • The efficacy was observed regardless of whether the mutation was identified by liquid or tissue biopsy.
  • Adverse events associated with tepotinib were manageable.
Keywords:
carcinomaliquid biopsynon-small-cell lungprotein kinase inhibitorsproto-oncogene proteins c-Mettepotinib

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
319